Who is sponsoring NCT03732365?

NCT03732365 is sponsored by Sonescence, Inc..

What drugs are being tested in NCT03732365?

Interventions in NCT03732365: Ultrasonic Drug Delivery, Standard of Care Antibiotic Treatment.

Is NCT03732365 still recruiting?

NCT03732365 is currently status unknown. Last updated 6 November 2018.

Last reviewed 2018-11-06 · How we verify

NCT03732365

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 2 Randomized Study to Compare Ultrasonic Drug Delivery to Standard of Care for the Treatment of Infections in Non-Healing Wounds

Status unknown Phase 2 Last updated 6 November 2018

What this trial tests

Phase 2 trial testing Ultrasonic Drug Delivery in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in 30 participants. Status unknown.

Timeline

1 February 2019

Primary endpoint
31 January 2020

31 July 2020

Quick facts

Lead sponsor	Sonescence, Inc.
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	30
Start date	1 February 2019
Primary completion	31 January 2020
Estimated completion	31 July 2020

Drugs / interventions tested

Ultrasonic Drug Delivery
Standard of Care Antibiotic Treatment — full drug profile →

Conditions studied

Acute Bacterial Skin and Skin Structure Infection (ABSSSI) — all drugs for Acute Bacterial Skin and Skin Structure Infection (ABSSSI) →
Non-healing Wound — all drugs for Non-healing Wound →

Sponsor

Sonescence, Inc. — full company profile →

Who can join

Adults 18 to 80, any sex, with Acute Bacterial Skin and Skin Structure Infection (ABSSSI) or Non-healing Wound. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized study to compare the safety and efficacy of a single dose of up to 2 grams of cefazolin administered using a new drug delivery method called Ultrasonic Drug Delivery (UDD), combined with standard of care (SOC) antibiotic therapy, oral or IV, compared to standard of care (SOC) antibiotic therapy alone, in treating chronic wounds with skin and soft tissue infection, containing gram-positive pathogens, in lower extremities.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sonescence, Inc. trials

Trials by the same sponsor.

NCT01238276 — Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersi · no longer available

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03732365 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sonescence, Inc.
Last refreshed: 6 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03732365.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing